3β-Ursodeoxycholic acid (Synonyms: isoUDCA, IUDCA, 3β-Ursodeoxycholic Acid) |
| カタログ番号GC61987 |
3β-Ursodeoxycholic acidはウルソデオキシコール酸（UDCA）の異性体であり、胆汁酸類に属する。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 78919-26-3
Sample solution is provided at 25 µL, 10mM.
3β-Ursodeoxycholic acidはウルソデオキシコール酸（UDCA）の異性体であり、胆汁酸類に属する[1]。3β-Ursodeoxycholic acidは、ミトコンドリア膜透過性遷移孔の開放を阻害し、カスパーゼカスカート反応を遮断し、PI3K/Aktとその他のシグナル経路を調節することで、肝細胞の損傷と肝臓の線維化を減らす[2-3]。3β-Ursodeoxycholic acidは主に、胆汁鬱滞性肝疾患と非アルコール性脂肪肝疾患の治療によく使われる[4]。
HepG2細胞で、3β-Ursodeoxycholic acid (100μM；24時間)は、エタノール誘発の細胞損傷に対して、細胞保護作用を持つ[1]。
胆管結紮ラットの胆汁鬱滞モデルで、3β-Ursodeoxycholic acid (2.5g/kg；経口；21日間)は、細胞/組織保護と胆汁酸を下げる作用を持つ[5]。
References:
[1]. Marschall HU, Roeb E, Yildiz Y, et al. Study of human isoursodeoxycholic acid metabolism. Journal of hepatology. 1997 Apr 1; 26(4): 863-870.
[2]. Purucker E, Marschall HU, Winograd R, et al. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. Biochimica et Biophysica Acta (BBA)-General Subjects. 2001 Apr 3; 1526(1): 44-52.
[3]. Zhang Y, Jiang R, Zheng X, et al. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation. British journal of pharmacology. 2019 Aug; 176(16): 2848-2863.
[4]. Li Y, Zhao J. Xiaohua Funing decoction ameliorates non-alcoholic fatty liver disease by modulating the gut microbiota and bile acids. Frontiers in Microbiology. 2025 Feb 10; 16: 1511885.
[5]. Purucker E, Marschall HU, Winograd R, et al. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. Biochim Biophys Acta. 2001 Apr 3; 1526(1): 44-52.
| 細胞実験[1]: | |
細胞株 | HepG2細胞 |
準備方法 | 3β--Ursodeoxycholic acidの体外細胞保護作用の解析 3β-Ursodeoxycholic acidの細胞保護作用の可能性を、ヒト肝芽腫細胞株HepG2を使った改良アッセイで体内研究した。よって、10% (v/v)ウシ胎児血清を添加したMEM（最小必須培地）で肝細胞長期培養物を培養し、エタノールと胆汁酸で処理した時は、無血清培地に交換した。 80 mMのエタノールと様々な胆汁酸(3β-Ursodeoxycholic acid, UDCA, cholic (CA), deoxycholic (DCA)またはchenodeoxycholic (CDCA) acids)（100μM）のある/ない状態で、肝芽腫細胞を24時間培養した。エタノールの毒性を、trypanブルー染色でテストした。 |
反応条件 | 100μM；24時間 |
アプリケーション | HepG2細胞で、3β-Ursodeoxycholic acidは、エタノール誘発の細胞損傷に対して細胞保護作用を持つ。 |
| 動物実験 [2]: | |
動物モデル | 胆管結紮ラット胆汁鬱滞モデル |
準備方法 | 220-250gの体重の36匹の雄のsprague dawleyラットを、二匹ごとにマクロロンケージに入れ、水と食物を自由に摂取させた。18匹をランダムに胆管結紮術を行い、もう18匹に模擬手術を行った。麻酔のために、Pentobarbital (40mg/kg)を腹腔内投与した。総胆管を1cmの右傍正中切開で露出させた。胆管結紮術を受ける動物で、総胆管を二回結紮し、十二指腸から1cmの近い位置に胆管傍膵管の結紮を避け、結紮部の間を切開する。対照群の動物で、結紮も解剖も行わなかった。胆管結紮術または模擬手術の6匹の動物群に、標準飼料または2.5g/kg UDCAあるいは2.5g/kg 3β-Ursodeoxycholic acidを添加した標準飼料を投与した。各サブグループは6匹の動物で構成された。6つのグループの食物摂取と体重（b.w.）を、21日間の実験で監視した。 |
投与形態 | 2.5g/kg；経口；21日間 |
アプリケーション | 3β-Ursodeoxycholic acidは、細胞/組織保護と胆汁酸を下げる作用を持つ。 |
References: | |
| Cas No. | 78919-26-3 | SDF | |
| 同義語 | isoUDCA, IUDCA, 3β-Ursodeoxycholic Acid | ||
| Canonical SMILES | C[C@@]12-;@[C@](-;@C-;@C-;@[C@]-;@2([H])[C@H](C)CCC(O)=O)([H])-;@[C@@]3([H])-;@[C@](-;@[C@@]4(-;@[C@](-;@C-;@[C@@H](O)-;@C-;@C-;@4)([H])-;@C-;@[C@@H]-;@3O)C)([H])-;@C-;@C-;@1 | ||
| Formula | C24H40O4 | M.Wt | 392.57 |
| 溶解度 | DMSO : 100 mg/mL (254.73 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5473 mL | 12.7366 mL | 25.4732 mL |
| 5 mM | 509.5 μL | 2.5473 mL | 5.0946 mL |
| 10 mM | 254.7 μL | 1.2737 mL | 2.5473 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *